证券代码：002044 证券简称：美年健康 公告编号：2024-100 美年大健康产业控股股份有限公司 第九届董事会第三次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 美年大健康产业控股股份有限公司（以下简称"公司"）第九届董事会第三次 （临时）会议经全体董事同意，会议于 2024 年 11 月 15 日下午 13:30 以通讯方式 召开。应出席本次会议的董事为 9 名，实际出席会议的董事为 9 名。会议由公司 董事长俞熔先生主持，公司监事及部分高级管理人员列席了会议。本次会议的出 席人数、召开表决程序、议事内容均符合《公司法》、《公司章程》等有关规定。 二、董事会会议审议情况 1、审议并通过《关于调整 2023 年股票期权激励计划行权价格的议案》 表决结果：赞成 7 票，反对 0 票，弃权 0 票。 公司董事会薪酬与考核委员会审议通过了该议案，北京市天元律师事务所对 该事项出具了法律意见，具体内容详见公司指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）。 《关于调整 2023 年股票期权激励计 ...

北京市天元律师事务所 关于美年大健康产业控股股份有限公司 2023 年股票期权激励计划行权价格调整、 预留股票期权授予事项的法律意见 京天股字（2023）第 617-2 号 致：美年大健康产业控股股份有限公司 北京市天元律师事务所（以下简称"本所"）接受美年大健康产业控股股份有限 公司（以下简称"美年健康"或"公司"）的委托，担任公司 2023 年股票期权激励计 划（以下简称"本次激励计划"）的专项法律顾问，为公司本次激励计划行权价格调 整及预留股票期权授予（以下简称"调整及预留授予"）相关事项出具本法律意见。 北京市天元律师事务所 关于美年大健康产业控股股份有限公司 2023 年股票期权激励计划行权价格调整、 预留股票期权授予事项的 法律意见 北京市天元律师事务所 北京市西城区金融大街 35 号 国际企业大厦 A 座 509 单元 邮编：100033 本所对公司提供的、本所认为出具本法律意见所需的文件进行了法律审查，就 公司股权激励计划的调整及预留授予以及与之相关的问题向相关人员进行了询问 或与之进行了必要的讨论，并对本次激励计划的调整及预留授予的合法、合规、真 实、有效性进行了核实验证。 本法律意见仅供美 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [2] Core Views - The company has achieved steady growth in the third quarter of 2024, with a revenue of 2.935 billion yuan, representing a year-on-year increase of 3.63%, and a net profit of 240 million yuan, up 10.33% year-on-year [6][9] - The company is focusing on enhancing service quality and optimizing customer structure through multi-channel marketing and innovative product development, aiming to meet the growing public demand for high-quality health management [7][8] - The company maintains its leading position in the health examination industry, with a total of 608 branches across more than 30 provinces, and continues to optimize its digital business processes [8] Financial Performance Summary - For the first three quarters of 2024, the company reported a total revenue of 7.141 billion yuan, a year-on-year decrease of 1.96%, and a net profit of 25 million yuan, down 88.96% year-on-year [6] - The projected revenues for 2024-2026 are 11.220 billion yuan, 12.877 billion yuan, and 14.397 billion yuan, with year-on-year growth rates of 3.0%, 14.8%, and 11.8% respectively [9][10] - The projected net profits for the same period are 480 million yuan, 803 million yuan, and 1.070 billion yuan, with year-on-year growth rates of -5.0%, 67.2%, and 33.3% respectively [9][10] Market Position and Strategy - The company is leveraging its operational advantages in professional, standardized, and large-scale health examination services to drive growth and enhance customer loyalty [8] - The company aims to create a new health management model that emphasizes personalized and sustainable health consumption, establishing a positive cycle of "professional examination - in-depth service - scientific customization - continuous repurchase" [8][9]

北京市天元律师事务所 关于美年大健康产业控股股份有限公司 2024 年第五次临时股东大会的法律意见 京天股字（2024）第 584 号 致：美年大健康产业控股股份有限公司 美年大健康产业控股股份有限公司（以下简称"公司"）2024 年第五次临时股东 大会（以下简称"本次股东大会"）采取现场记名投票表决与网络投票表决相结合的 方式，现场会议于 2024 年 11 月 8 日（星期五）下午 14:50 在上海市静安区灵石路 697 号健康智谷 9 号楼三楼公司会议室召开。北京市天元律师事务所（以下简称"本 所"）接受公司聘任，指派本所律师参加本次股东大会现场会议进行见证，并根据 《中华人民共和国公司法》、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东大会规则（2022 年修订）》（以下简称"《股东大会规则》"）以及 《美年大健康产业控股股份有限公司章程》（以下简称"《公司章程》"）等有关规 定，就本次股东大会的召集、召开程序、出席现场会议人员的资格、召集人资格、 会议表决程序及表决结果等事项出具本法律意见。 为出具本法律意见，本所律师审查了《美年大健康产业控股股份有限公司第九 届董事会第一次 ...

证券代码：002044 证券简称：美年健康 公告编号：2024-099 美年大健康产业控股股份有限公司 2024 年第五次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决或修改提案的情况，无涉及变更前次股东大会决议的 情况。 2、本次股东大会审议的议案1，出席会议的关联股东均已回避表决。 3、本次股东大会审议的全部议案已对中小投资者（指除上市公司的董事、监 事、高级管理人员以及单独或者合计持有上市公司5%以上股份的股东以外的股东） 的表决单独计票。 1）通过深圳证券交易所交易系统进行网络投票的具体时间为 2024 年 11 月 8 日 9:15-9:25，9:30-11:30 和 13:00-15:00； 2）通过互联网投票系统进行网络投票的具体时间为 2024 年 11 月 8 日 9:15- 15:00 的任意时间。 2、现场会议召开地点：上海市静安区灵石路 697 号健康智谷 9 号楼三楼公司 会议室 3、召开方式：现场投票与网络投票相结合的方式 4、会议召集人：公司董事会 一、会议召开和出席情况 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a significant improvement in profitability in Q3 2024, with a year-on-year increase in net profit of 10.3% and a gross profit margin of 45.43% [2][3] - The company is focusing on an "innovation-driven" development strategy, launching specialized health examination projects and AI-driven health management products, including the "Health Xiaomei" AI robot [3] - The number of branches continues to expand, with a total of 608 branches as of September 30, 2024, maintaining a leading position in the industry in terms of coverage and examination volume [3] Financial Performance Summary - For the first three quarters of 2024, the company achieved a revenue of 7.141 billion yuan, a decrease of 1.96% year-on-year, and a net profit of 25 million yuan, down 88.96% [2] - In Q3 2024 alone, the company reported a revenue of 2.935 billion yuan, an increase of 3.63% year-on-year, and a net profit of 240 million yuan, up 10.33% [2] - The company's revenue forecast for 2024-2026 has been adjusted, with expected net profits of 400 million yuan, 703 million yuan, and 999 million yuan for the respective years [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a strong performance in Q3, with innovative business models continuing to empower growth. The revenue for Q3 was 2.935 billion yuan, a year-on-year increase of 3.63%, and the net profit attributable to shareholders was 240 million yuan, up 10.33% year-on-year [1] - The company has maintained a leading position in the private health examination sector, leveraging big data and AI technology to drive business innovation. The upcoming peak season for health examinations is expected to support continued positive growth in performance [1] Financial Performance Summary - For the first three quarters of 2024, the company achieved a total revenue of 7.141 billion yuan, a decrease of 1.96% year-on-year, and a net profit attributable to shareholders of 25 million yuan, down 88.96% year-on-year. However, the net profit excluding non-recurring items was 8 million yuan, an increase of 96.43% year-on-year [1] - The company’s gross profit margin for the first three quarters of 2024 was 39.67%, an increase of 4.02 percentage points from the first half of 2024. The net profit margin was 1.13%, up 6.10 percentage points from the first half of 2024 [1] - The company plans to achieve revenues of 11.470 billion yuan, 12.866 billion yuan, and 14.260 billion yuan for the years 2024, 2025, and 2026, respectively, with year-on-year growth rates of 5.3%, 12.2%, and 10.8% [3][4] Business Development Summary - As of September 30, 2024, the company had a total of 608 branches across more than 30 provinces, maintaining the highest number of health examination visits in the industry. The company has also launched the first health management robot in collaboration with Huawei and RunDa Medical, enhancing its competitive edge [1] - The company is expected to continue benefiting from the integration of AI technology into its health examination services, which is anticipated to improve customer pricing and overall business performance [1]

2024 年 11 月 05 日 公司研究 评级：买入(维持) 研究所： 证券分析师： 李明 S0350523090001 lim06@ghzq.com.cn [Table_Title] 第三季度营收利润双增长，发布国内首个 AI 数 智健管师"健康小美" ——美年健康（002044）公司动态研究 最近一年走势 事件: 美年健康于 10 月 31 日发布 2024 年三季报：2024 年第三季度公司实现 收入 29.35 亿元（+3.63%，同比口径，下同），归母净利润 2.40 亿元 （+10.33%）。 投资要点: 业绩逐季改善，第三季度实现收入、利润同步增长。健康体检行业 具有明显的季节性，一季度为业务淡季，且由于去年一季度基数较 高，导致今年一季度业绩同比下滑；二季度实现营收同比正增长； 三季度实现收入、利润均同比正增长；四季度是体检行业旺季，公 司发展态势良好。 相对沪深 300 表现 2024/11/04 表现 1M 3M 12M 美年健康 8.8% 27.3% -22.0% 沪深 300 -1.8% 16.6% 10.1% 持续推出创新项目与健管服务，发布"健康小美"AI 数智健管师。 公司已有 ...

证券代码：002044 证券简称：美年健康 公告编号：2024-098 美年大健康产业控股股份有限公司 关于召开 2024 年第五次临时股东大会的提示性公告 1、股东大会届次：公司 2024 年第五次临时股东大会。 2、股东大会召集人：公司第九届董事会第一次（临时）会议决议召开，由 公司董事会召集。 3、会议召开的合法、合规性：本次股东大会的召集、召开及审议事项符合 《中华人民共和国公司法》、《中华人民共和国证券法》、《深圳证券交易所股 票上市规则》等法律、行政法规及《公司章程》等规定，提案内容明确并在法定 期限内公告。 4、会议召开的日期、时间： （1）现场会议召开时间：2024 年 11 月 8 日（星期五）下午 14:50。 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 美年大健康产业控股股份有限公司（以下简称"公司"）2024 年第五次临时股 东大会现场会议的召开地点为上海市静安区灵石路 697 号健康智谷 9 号楼三楼 公司会议室，敬请投资者特别留意。 根据公司于 2024 年 10 月 15 日召开的第九届董事会第一次（临时）会议 ...

Investment Rating - Buy rating maintained for the stock [2] Core Views - The company's Q3 2024 revenue reached RMB 2.935 billion (+3.63% YoY), with net profit attributable to shareholders of RMB 240 million (+10.33% YoY), slightly exceeding expectations [3] - Revenue growth is expected to improve in Q4 due to the peak season for health check-up services, with stable order volume and increasing average customer spending [3] - Gross margin improved to 45.43% in Q3 2024 (+1.12 pct YoY), with net profit margin rising to 8.19% (+0.5 pct YoY) [3] - Operating cash flow improved to RMB 289 million in Q3 2024 (+4.05% YoY), with cash and cash equivalents balance reaching RMB 1.46 billion (+3.14% YoY) [3] - AI products, including the "Health Xiaomei" AI health management robot and AI smart glucose management system, have been launched and are being piloted in 26 branches [4] Financial Projections - Revenue is projected to grow to RMB 11.008 billion in 2024, RMB 11.837 billion in 2025, and RMB 12.687 billion in 2026 [5] - Net profit attributable to shareholders is expected to reach RMB 333 million in 2024, RMB 629 million in 2025, and RMB 895 million in 2026 [5] - EPS is forecasted at RMB 0.09 in 2024, RMB 0.16 in 2025, and RMB 0.23 in 2026 [5] - P/E ratios are projected at 55.12x for 2024, 29.2x for 2025, and 20.52x for 2026 [5] Financial Ratios and Performance - Gross margin is expected to improve from 42.5% in 2024 to 45.3% in 2026 [8] - Net profit margin is projected to increase from 3.0% in 2024 to 7.1% in 2026 [8] - ROE is forecasted to rise from 4.1% in 2024 to 9.4% in 2026 [8] - Asset-liability ratio is expected to decline from 56.4% in 2024 to 52.9% in 2026 [8] AI and Innovation - The company has partnered with Huawei to launch the "Health Xiaomei" AI health management robot, which is currently being piloted in 26 branches [4] - AI-driven products, such as the AI smart glucose management system and AI sales assistant "Meinian Xiaoxing," are expected to enhance operational efficiency and customer engagement [4]